Metformin in Post Chronic Pancreatitis Diabetes Mellitus
Key facts
- Who runs it
- Changhai Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 58 people, planned
- Started
- 28 Apr 2025
- Planned end
- 31 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Metformin
- Placebo
- Record updated
- 21 May 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Aged 18-65 years, any sex
- Patients diagnosed with chronic pancreatitis
- Diagnose diabetes at least 3 months after chronic pancreatitis diagnosis
- Never used any diabetes drug/glucose-lowering medication or had discontinued any glucose-lowering medications for at least 8 weeks prior to screening
- HbA1c criteria: 7.5%~9.0%
- BMI >18.5
- Provision of signed informed consent
Who cannot take part
- Acute episodes of chronic pancreatitis at enrollment or within 3 months prior to enrollment
- Previous organ transplantation
- Treatment with oral or systemic glucocorticoids within 3 months prior to enrollment or plan to use during the study (inhaled steroids are permitted)
- Type 1 diabetes or secondary diabetes not caused by chronic pancreatitis (e.g. diabetes due to monogenic defects, cystic fibrosis, medications, autoimmune diseases, stress, or other factors)
- Contraindications or history of intolerance or allergy to metformin
- History of congestive heart failure (NYHA class 3 or greater), unstable angina, or other severe cardiovascular diseases
- History of cancer (except non-melanoma skin cancer) within 5 years prior to screening
- History of partial or total pancreatectomy
- History of or planning bariatric surgery
- Sever psychiatric disorders or health conditions deemed unsuitable for clinical research participation
- Any other condition considered by the investigator to be inappropriate for participation in the trial
- History of hemolytic anemia, chronic transfusion requirements, or other conditions rendering HbA1c results unreliable
- Other conditions requiring glucose-lowering medications, such as polycystic ovary syndrome
- Fasting blood glucose >11.1 mmol/L during screening, requiring immediate treatment as judged by the physician
- Fasting C-peptide <0.3 nmol/L
- Pregnancy or plans for pregnancy during the course of the study
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the efficacy and safety of metformin in treating patients with post chronic pancreatitis diabetes mellitus (PPDM-C). The main questions it aims to answer are:
Read full original descriptionShow less
* What is the efficacy of metformin in glycemic control in patients with PPDM-C? * What is the incidence of adverse effects associated with metformin in patients with PPDM-C?
Participants will be randomly assigned to receive either metformin or a placebo to see if metformin provides significant glycemic control and to assess the safety profile of the treatment.
The 2 groups in the trial
- MetforminTreatment being tested
Participants are administered metformin with an initial dose of 500 mg/day, which was incrementally increased by 500 mg/day each week until the maximum tolerated dose. The maximum dose of metformin is set at 2000 mg/day. After 2 weeks of administration, participants will undergo safety assessments, including complete blood count, urinalysis, liver function tests, and renal function tests. After attainment to a stable dose of metformin, participants will undergo follow-up assessments at 4 weeks, 8 weeks, and 12 weeks. The final evaluation of outcome measures will be completed at the 12-week follow-up.
- PlaceboPlacebo, for comparison
Participants are administered a placebo, starting with one tablet per day, followed by an incremental increase of one tablet per week. In the absence of adverse reactions, the dosage is escalated up to a maximum of four tablets per day. After 2 weeks of administration, participants will undergo safety assessments, including complete blood count, urinalysis, liver function tests, and renal function tests. After attainment to a stable dose, participants will undergo follow-up assessments at 4 weeks, 8 weeks, and 12 weeks. The final evaluation of outcome measures will be completed at the 12-week follow-up.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Metformin in Post Chronic Pancreatitis Diabetes Mellitus: a Double-blind, Randomized, Placebo-controlled Trial
- Criteria questions
- Built from NCT06937294, who can take part
- Record updated
- 21 May 2025